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Summary
Expression of the adhesion molecule, CD146/MCAM/MelCAM, on T cells
has been associated with recent activation, memory subsets and T helper
type 17 (Th17) effector function, and is elevated in inflammatory arthritis.
Th17 cells have been implicated in the pathogenesis of rheumatoid arthritis
(RA) and spondyloarthritides (SpA). Here, we compared the expression of
CD146 on CD4+ T cells between healthy donors (HD) and patients with RA
and SpA [ankylosing spondylitis (AS) or psoriatic arthritis (PsA)] and
examined correlations with surface markers and cytokine secretion. Periph-
eral blood mononuclear cells (PBMC) were obtained from patients and
controls, and synovial fluid mononuclear cells (SFMC) from patients.
Cytokine production [elicited by phorbol myristate acetate (PMA)/
ionomycin] and surface phenotypes were evaluated by flow cytometry.
CD146+CD4+ and interleukin (IL)-17+CD4+ T cell frequencies were
increased in PBMC of PsA patients, compared with HD, and in SFMC com-
pared with PBMC. CD146+CD4+ T cells were enriched for secretion of
IL-17 [alone or with IL-22 or interferon (IFN)-γ] and for some putative
Th17-associated surface markers (CD161 and CCR6), but not others (CD26
and IL-23 receptor). CD4+ T cells producing IL-22 or IFN-γ without IL-17
were also present in the CD146+ subset, although their enrichment was less
marked. Moreover, a majority of cells secreting these cytokines lacked
CD146. Thus, CD146 is not a sensitive or specific marker of Th17 cells, but
rather correlates with heterogeneous cytokine secretion by subsets of CD4+
helper T cells.
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Introduction
Interleukin (IL)-17-secreting T helper type 17 (Th17) cells
produce a distinct set of proinflammatory cytokines,
including IL-17A, IL-17F and IL-21, which normally regu-
late immunity at intestinal barriers and enable defence
against extracellular bacteria and fungi [1]. Th17 cells dif-
ferentiate from naive CD4+ T cells under the combined
control of proinflammatory myeloid- and tissue-derived
cytokines, such as IL-1, IL-6, transforming growth factor
(TGF)-β and/or IL-23. They express characteristic surface
markers, such as the chemokine receptors, CCR6 and
CCR4, the receptor for IL-23 and CD161 [2,3]. The
sensitivity and specificity of these and other markers for
Th17 cells continue to be investigated.
Th17 cells have been implicated in a wide range of auto-
immune and inflammatory diseases [4]. Evidence for their
importance in pathogenesis comes from gene ablation and
cell transfer studies in animal models, genomewide associa-
tion studies and phenotypical and functional analysis of
patients’ T cells. However, Th17 responses appear to be dis-
pensable for other autoimmune diseases, such as type 1 dia-
betes [5]. Among rheumatological conditions with a
recognized Th17 component are rheumatoid arthritis (RA)
and the spondyloarthritides (SpAs), a group of related con-
ditions including ankylosing spondylitis (AS), psoriatic
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arthritis (PsA), arthritis related to inflammatory bowel
disease, reactive arthritis and a subgroup of juvenile
idiopathic arthritis.
In human inflammatory arthritides and in mouse models
of these diseases, Th17 cells contribute to tissue inflamma-
tion; the IL-17 they produce plays an important role in
recruitment of other leucocytes to sites of inflammation
[6]. In patients with SpA, an increased frequency of Th17
cells is found in the peripheral circulation, with further
enrichment in affected joints [7–10]. Genomewide associa-
tion studies suggest altered regulation of Th17 differentia-
tion or fate in AS [11]. Higher levels of IL-23 or increased
IL-23R signalling could contribute [12]. Another potential
mechanism involves signalling by misfolded B27 to Th17
cells, by aberrant interactions with surface receptors [13] or
by induction of IL-23 secretion due to endoplasmic reticu-
lum stress. Anti-IL-17 monoclonals have shown early signs
of therapeutic efficacy in PsA and AS, indicating a key role
for this cytokine [14]. Similarly, animal models, as well as
phenotypical and functional studies and clinical trials in
humans, point towards derangement of Th17 cells in RA
[6,7,14]. Genomic evidence for specific Th17 involvement
in RA is less extensive, but polymorphisms in the IL-6 sig-
nalling pathway and in the Th17-related chemokine recep-
tor, CCR6, have been reported; other gene associations
point towards suboptimal regulation of T cell activation
[15].
More recent work has highlighted the heterogeneity of
IL-17-secreting helper T cells. Many IL-17-producing cells
are unable to produce interferon (IFN)-γ or IL-22, which
used to be thought of as defining separate Th1 and Th22
effector cell populations, respectively. However, other IL-17-
secreting CD4+ T cells do produce these cytokines, suggest-
ing heterogeneity or plasticity of Th17 cell cytokine
secretion patterns [7]. In-vitro studies and fate-mapping
experiments in mice have demonstrated that Th17 cells can
acquire IFN-γ secretion, and subsequently lose the ability to
secrete IL-17 (‘ex-Th17 cells’), under the influence of IL-23
and chronic antigenic stimulation [16]. IL-17+ IFN-γ−
Th17 cells have been associated with anti-bacterial
immunity, whereas autoimmunity may be associated with
‘bifunctional’, IL-17+ IFN-γ+ and/or IL-17+ IL-22+ CD4
T cells [17].
CD146/melanoma cell adhesion molecule (MelCAM) is
an immunoglobulin (Ig) superfamily molecule, which is
highly expressed at tight junctions of endothelial cells and
on surfaces of vascular smooth muscle and trophoblast
cells. CD146 has important functions in adhesion, tissue
invasion and signalling [18,19]. In the human immune
system, it is expressed on ≈2% of circulating T cells ex vivo
[20] and induced upon polyclonal activation in vitro [21].
Circulating CD146+CD4+ T cells have an effector memory
phenotype, expressing CD45RO but not CCR7; they
are enriched for markers of recent activation ex vivo [22].
These studies, alongside endothelial adhesion experiments
[22–24], suggest an important role for CD146 in
transendothelial migration of certain activated Th cell
subsets to sites of inflammation. A recent study showed that
laminin-411 in vascular basement membranes interacts
with CD146 on T cells to facilitate transmigration to
inflammatory sites [25].
Patients with some inflammatory diseases (Behçet’s
disease, sarcoidosis and Crohn’s disease) have significantly
higher frequencies of CD146+ T cells in peripheral blood
than healthy individuals [26]. Patients with RA and other
inflammatory arthritides also have elevated CD146+ T cell
frequencies in blood, and even higher frequencies at sites of
inflammation [21,27]. Similarly, in our recent study of
patients with several autoimmune connective tissue dis-
eases, CD146 expression on circulating T cells was associ-
ated with effector memory phenotypes, and increased
frequencies were observed in a subset of patients with
marked T cell activation [28]. High levels of soluble CD146
have been detected in synovial fluid of patients with RA
[29], although this may be shed by activated endothelia, as
well as infiltrating CD146+ T cells.
Several recent studies link CD146 expression with Th17
effector function. In multiple sclerosis, the frequency of
CD146 expression is higher in Th17 cells than in Th1 cells
[24]. Conversely, cells producing IL-17, IL-22 and (to a
lesser extent) IFN-γ are enriched within the CD146+ subset
of CD4+ T cells [25]; moreover, some of the transcripts
selectively enriched in CD146+ T cells are Th17-related
[22,26,27]. Some of these studies proposed that CD146 is a
Th17-associated cell surface marker, either alone [25] or in
combination with other markers [30]; others, however, were
careful to point out that not all IL-17-secreting Th cells
express CD146 [26]. Here, we examined the relationship
between CD146 expression, production of IL-17 with or
without IL-22 and IFN-γ and the expression of putative
Th17-associated surface markers by CD4+T cells in patients
with SpA (PsA and AS) and RA and in blood from healthy
donors.
Materials and methods
Patients
Peripheral blood was obtained from 16 patients with PsA
[seven female, nine male; age = 44 ± 11 years; mean ±
standard deviation (s.d.)], 10 patients with AS (three
female, seven male; mean age, 45 ± 16 years), 14 patients
with RA (nine female, five male; mean age, 56 ± 17 years)
and 22 healthy donors (HDs; eight female, 14 male; mean
age, 38 ± 10 years). Mean ages did not differ significantly
between groups (P > 0·05), except for RA versus HD
[P = 0·001, one-way analysis of variance (anova) with
Holm–Sidak post-test for all pairwise comparisons].
Synovial fluid was collected, in most instances on separate
occasions, from 10 patients with PsA, four with AS and four
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with RA. Patients met CASPAR (ClASsification criteria for
Psoriatic Arthritis) classification criteria for PsA [31], the
modified New York criteria for AS [32] or the 2010 Ameri-
can College of Rheumatology/European League Against
Rheumatism classification criteria for RA [33]. Patients
were recruited through out-patient clinics at Addenbrooke’s
Hospital, Cambridge, UK. They were being treated with
biologicals, anti-inflammatory and immunosuppressive
agents, and (in some RA patients) corticosteroids, alone or
in combination. Erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) were measured at the time of
venepuncture in a majority of patients. The study was
approved by Cambridge University Hospitals’ Regional
Ethical Committee, and written informed consent was given
by all patients.
Preparation and stimulation of mononuclear cells
Peripheral blood and synovial fluid mononuclear cells
(PBMC and SFMCs, respectively) were prepared by cen-
trifugation over a Ficoll-Hypaque gradient (Amersham
Pharmacia Biotech, Little Chalfont, UK) and cryopreserved
in 10% dimethylsulphoxide (DMSO) in fetal bovine serum
(FBS). Thawed cells were routinely >90% viable by Trypan
Blue exclusion.
For cytokine secretion assays, PBMC were thawed in
warm media and adjusted to a final concentration of
2 × 106/ml in RPMI-1640 medium supplemented with 10%
v/v heat-inactivated fetal calf serum, 2 mM glutamine,
penicillin/streptomycin and 20 mM HEPES. The cells were
seeded into 24-well culture plates (Nunc, Naperville, IL,
USA), stimulated with phorbol myristate acetate (PMA;
50 ng/ml; Sigma, St Louis, MO, USA) and calcium
ionomycin (1 μg/ml) (Sigma) for 5 h, and treated with
GolgiStop monensin at 2·25 μM final concentration
(Becton Dickinson, Mountain View, CA, USA), at the same
time as the stimulation.
Immunofluorescent staining and flow cytometry
Eight-colour flow cytometry was used to analyse the surface
phenotype and intracellular cytokine production of PBMC
and SFMC. The antibodies used were as follows: for surface
staining, allophycocyanin-cyanin 7 (APC-Cy7)-labelled
anti-CD3 (Becton Dickinson), biotin-labelled anti-CD4
(Biolegend, San Diego, CA, USA) used with Qdot655-
streptavidin (Invitrogen, Carlsbad, CA, USA), phycoery-
thrin (PE)-labelled anti-CD146 (Becton Dickinson,
Franklin Lakes, NJ, USA), fluorescein isothiocyanate
(FITC)-labelled anti-CD161 (Biolegend), peridinin
chlorophyll (PerCP)-Cy5·5-labelled anti-CCR6 (Becton
Dickinson), FITC-labelled anti-CD26 (Becton Dickinson),
PE-Cy5-labelled anti-CXCR3 (Becton Dickinson) and APC-
labelled anti-IL-23R (R&D Systems, Minneapolis, MN,
USA); for intracellular cytokine detection, PE-Cy7-labelled
anti-IL-17A (Becton Dickinson), effluor660-labelled anti-
IL-22 (eBioscience) and Pacific Blue-labelled anti-IFN-γ
(eBioscience, San Diego, CA, USA). Appropriately conju-
gated IgG antibodies were used as isotype controls.
Cells were first stained with antibodies against surface
antigens and then fixed and permeabilized using Perm/Fix
solution (Becton Dickinson). Cells were washed with Perm/
Wash buffer (Becton Dickinson) and stained with antibod-
ies against intracellular cytokines. Flow cytometric analysis
was performed using a FACSCanto II analyser (Becton
Dickinson). CD3+CD4+T lymphocytes or their CD146+ and
CD146− subsets were gated within a scatter gate drawn nar-
rowly on intact lymphocytes and frequencies of cells
expressing surface markers or cytokines of interest, alone or
in combination, were determined using quadrant statistics
in FlowJo version 7·6 software (Tree Star, Inc., Ashland, OR,
USA).
Statistical analysis
Statistical analyses were performed using Prism (version
5·0; GraphPad Software, San Diego, CA, USA). Generally,
medians and interquartile ranges were used as summary
statistics, and non-parametric tests (Mann–Whitney U-test
or Kruskal–Wallis anova with Dunn’s post-test for multi-
ple comparisons) were used for comparison between
groups. To evaluate the relationship of CD146 to other
markers in different patient groups, two-way anova was
performed using log-transformed data, if necessary, to
equalize variances; geometric mean frequencies were
reported with 95% confidence intervals. Pearson’s linear
regression was used to correlate immunophenotypes with
each other and with inflammatory markers.
Results
Circulating CD146+ CD4+ T cells are elevated in some
patients with arthritis
In order to quantify CD146 expression by CD4 T cells,
PBMCs were isolated from patients with RA or SpA and
from healthy controls, and cryopreserved. CD3+CD4+ cells
were identified within a lymphocyte scatter gate (Fig. 1a)
and the percentage of CD146+ cells determined within this
population (Fig. 1b). CD146 staining appeared specific
compared with isotype controls (Fig. 1a). This analysis was
performed in PBMCs from HDs (n = 22), patients with SpA
(AS, n = 10; or PsA, n = 16) and patients with RA (n = 14).
Representative examples of CD146 staining are shown in
Fig. 1b and a summary in Fig. 1c. Some patients with
inflammatory arthritis had markedly higher frequencies of
CD146+ T cells in the CD4 subset than healthy controls. The
median increase above HDs was statistically significant in
SpA patients, analysed together (P < 0·05, Kruskal–Wallis
anova with Dunn’s post-test; Fig. 1c). When treated as
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separate groups, the increase reached statistical significance
in PsA (P < 0·05), but not in AS, the smallest of the patient
groups (data not shown).
The same analysis showed no significant increase in
median CD146 frequency in RA patients, but six of 14 RA
patients had CD146+CD4+ T cell frequencies above 3·5%,
whereas only one of 22 HDs exceeded this value
(P = 0·0083, Fisher’s exact test). (Note that the use of this
cut-off is based on the distribution observed in HDs, which
was consistent with previous studies from our laboratory
[28].) In conclusion, increased frequencies of CD146+CD4+
cells are seen in a proportion of patients with inflammatory
arthritis.
The small size of the study group limited clinical correla-
tions, but the frequencies of CD146+CD4+ T cells correlated
with erythrocyte sedimentation rate (ESR; r2 = 0·17,
P = 0·022 for all patients with arthritis; Fig. 2a). There was
no significant correlation with C-reactive protein (CRP),
however (data not shown). When RA patients alone were
analysed, the frequencies of CD146+CD4+ T cells correlated
with ESR (r2 = 0·46, P = 0·008) and with swollen joint count
(r2 = 0·41, P = 0·024; Fig. 2b,c). These data suggest that the
CD146+ phenotype of circulating CD4+ T cells is related to
the inflammatory process.
IL-17, IL-22 and IFN-γ secretion is differentially
enriched in the CD146+ Th subset
In order to examine the relationship of CD146 expression
with effector cytokine expression, PBMCs were stimulated
with PMA/ionomycin in the presence of monensin for 5 h;
surface-stained for CD3, CD4 and CD146; fixed and
permeabilized; and stained for intracellular IL-17, IL-22 and
IFN-γ. CD146 expression is known to be induced following
in-vitro activation for >16 h [18,28], but no CD146 induc-
tion was detected at 5 h, when compared with ex-vivo
surface-staining. A representative example from an SpA
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patient is shown in Fig. 3a. Supporting information, Fig. S1,
shows a close correlation between CD146+ CD4 cell fre-
quencies ex vivo and post-stimulation (Supporting infor-
mation, Fig. S1a). No significant effect of stimulation was
detected, whether in a pooled analysis of paired data (Sup-
porting information, Fig. S1b) or after stratification into
patient groups (Supporting information, Fig. S1c).
In all groups, a majority of CD146+ peripheral blood
lymphocytes, and almost all IL-17-secreting lymphocytes,
were within the CD4+ population; a representative example
from the same SpA patient is shown in Fig. 3b. Secretion of
IL-17, IL-22 and IFN-γ by CD4+ T cells was readily detect-
able (examples shown for the same patient in Fig. 3c). The
median frequency of IL-17-secreting CD4+ T cells was
approximately doubled in SpA compared with HDs
(P < 0·05), but the difference in RA was not statistically sig-
nificant (Fig. 3d). Within the SpA group, both PsA and AS
patients showed increased frequencies of IL-17-secreting
cells (data not shown). Increased secretion of IL-22 and
IFN-γ by CD4+ T cells in arthritis patients was less
pronounced and did not reach statistical significance
(Fig. 3e,f).
Flow cytometry clearly showed that effector cytokines
were secreted both by CD146+ and CD146−CD4+ T cells
(Fig. 3c). If CD146 and cytokines are expressed indepen-
dently of each other, then the percentage of cytokine-
expressing CD4 T cells should not differ between CD146+
and CD146− cells. However, a much greater proportion of
CD146+ than CD146−CD4 T cells produced IL-17, both in
HDs and in patients with SpA and RA (Fig. 4a). The enrich-
ment of IL-17 secretors in the CD146+ population was ≈18-
fold in HDs, ≈13-fold in SpA and ≈7·4-fold in RA
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(geometric means). The overall increase in Th17 frequen-
cies in SpA was not related specifically to either the CD146+
or the CD146− subset.
Similar analyses were performed for other effector
cytokines. IL-22 secretion by CD4 T cells was associated sig-
nificantly with CD146 expression, although the fold enrich-
ments were less (8·5, 4·8 and 4·8, respectively, in the HD,
SpA and RA groups; Fig. 4b). Even less enrichment within
the CD146+ CD4 subset was observed for IFN-γ (2·5-, 1·7-
and 1·8-fold in the three groups; Fig. 4c). However, the
frequency of IFN-γ producers was much higher overall;
therefore, in the CD146+ subset, IFN-γ producers were at
least as abundant as IL-17 producers.
Conversely, we asked what proportion of cytokine-
producing cells expressed CD146. CD146+CD4+ T cells
accounted, on average, for ≈18%–31% of IL-17-producing
Th cells, both in arthritis patients and HDs (Table 1). Simi-
larly, CD146+ cells comprised just greater than 10% of
IL-22-producing CD4+ T cells, and approximately 3–5% of
IFN-γ producers, in patients and controls (data not shown).
Thus, CD146 was not a sensitive cell surface marker of
Th effector cells in general, nor of any one Th subset in
particular.
Dual cytokine secretion in the CD146+ subset of
circulating CD4+ T cells
Individual human effector Th cells may secrete multiple
cytokines, including combinations that, historically, had
been classified as belonging to distinct helper cell subsets
(e.g. IL-17 with the Th1 ‘signature cytokine’, IFN-γ). In our
study, approximately 15–20% of IL-17-secreting CD4 T
cells also secreted IL-22 or IFN-γ, as shown for a representa-
tive SpA patient in Fig. 5a (left panels). Accordingly, in a
proportion of patients and controls, we compared the fre-
quencies of dual cytokine-secreting cells (upper right quad-
rants) between CD146+ and CD146−CD4 T cells (Fig. 5a,
right and far right panels). In HDs and the different patient
groups, IL-17/IL-22 dual secretors were enriched by 15–22-
fold within the CD146+ subset (geometric means), com-
pared to CD146− cells (summarized in Fig. 5b). A similar
degree of enrichment was seen for IL-17/IFN-γ dual
secretors in the CD146+ subset (13–21-fold; Fig. 5c). These
fold enrichments for bifunctionality were at least as high as
for IL-17 producers overall (cf. Fig. 4a). Together, the data
in Figs 4 and 5 suggest that effector cytokine secretion by
CD146+CD4+ T cells is heterogeneous, and that CD146 is
not a specific marker of Th-17-only cells, producing IL-17
without IFN-γ or IL-22.
CD146+CD4+ circulating T cells are enriched in some
putative Th17-related cell surface markers
The expression of selected putative Th17 surface markers
(CCR6, CD26, CD161 and IL-23R, with CXCR3 as a
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negative control) was compared between CD146+ and
CD146− CD4+ T cells, as well as with IL-17+CD4+ T cells.
CD146 was co-expressed with CCR6 and CD161, as
shown for a representative SpA patient in Fig. 6a. Com-
pared to CD146− cells, CD146+ cells were significantly
enriched for CCR6 and CD161: 40–60% of CD146+ cells
were CCR6+ and 30–40% were CD161+ (Fig. 6b,c). CCR6
(but not CD161) expression also differed between patient
groups (lower expression in the arthritides; P = 0·0004),
although this effect was smaller in magnitude (Fig. 6b).
An even greater majority of IL-17-secreting CD4+ T cells
expressed CCR6; approximately half also expressed CD161
(Fig. 6b,c). Both CCR6 and CD161 were thus expressed by a
greater proportion of IL-17+CD4+ T cells than CD146 (18–
31%; Table 1). Thus, of these markers, CCR6 was the most
sensitive individual marker of IL-17 production by CD4+ T
cells, followed by CD161 and CD146.
However, CD161 and CCR6 exhibited lower specificity
for Th17 cells than CD146: a significant proportion of
IL-17-negative cells expressed these markers, and their
enrichment within the IL-17-secreting cells was only 3–4-
fold, much lower than the ≈9–11-fold enrichment observed
for CD146 (Table 1).
Other putative Th17 markers were not associated with
CD146 expression (Supporting information, Fig. S2). CD26
was present on ≈70% of both CD146+ and CD146− cells,
and even more highly expressed (≈80%) on IL-17-secreting
cells (Supporting information, Fig. S2a). CXCR3, which is
not related to Th17 cells, was expressed on a minority of
CD4 T cells, regardless of CD146 expression (Supporting
information, Fig. S2b). (The relationship of CXCR3 expres-
sion to IL-17 could not be evaluated, because stimulation
with PMA and ionomycin resulted in rapid down-
regulation of CXCR3 expression on all CD4+ cells.) The
receptor for IL-23, a key cytokine for differentiation, expan-
sion and maintenance of Th17 cells, was expressed on only
a minority of IL-17-producing CD4 cells, and in similar,
low proportions of CD4 cells with or without CD146 (Sup-
porting information, Fig. S2c). In conclusion, only some
surface markers previously implicated in Th17 differentia-
tion or function were expressed selectively on the CD146-
expressing subset.
In addition, we investigated the relationship between
IL-17 secretion and CD146 co-expression with either CCR6
or CD161. IL-17+CD4+ or IL-17−CD4+ T cells were gated,
and expression of these surface markers was evaluated
Table 1. Co-expression of CD146 with either CCR6 or CD161 in peripheral blood: comparison between interleukin (IL)-17+ and IL-17− T helper
cells.
Group
Marker
(combination)
% in IL-17+CD4+ T cells % in IL-17–CD4+ T cells Ratio
Median IQR Median IQR Median IQR
HD (n = 17) CD146+ 18·1 (14·1–28·3) 1·7 (1·4–2·5) 10·9 (9–12·1)
CCR6+ 83·1 (66·4–90·7) 18·4 (14·1–33·5) 2·9 (2·0–5·9)
CD146+CCR6+ 16·5 (13·4–26·5) 1·1 (0·6–1·3) 20·8 (11·5–24·2)
CD161+ 53·8 (39·1–60·6) 13·9 (10·6–19·3) 3·3 (2·7–4·5)
CD146+CD161+ 13·4 (10·6–17·4) 0·8 (0·5–1·1) 15·3 (11·8–21·3)
PsA (n = 12) CD146+ 31·0 (23·8–38·7) 2·7 (2·0–4·0) 9·9 (9·3–10·9)
CCR6+ 73·8 (63·0–80·7) 30·0 (22·7–32·7) 2·5 (2·1–2·9)
CD146+CCR6+ 21·7 (17·5–28·3) 1·7 (1·1–2·5) 14·1 (10·2–16·2)
CD161+ 52·8 (41·3–63·7) 13·3 (9·3–19·8) 3·8 (3·2–5·1)
CD146+CD161+ 18·2 (14·6–22·4) 1·0 (0·5–1·7) 15·0 (11·4–20·3)
AS (n = 7) CD146+ 31·1 (26·0–35·8) 3·2 (3·0–4·0) 8·7 (6·8–10·2)
CCR6+ 88·1 (85·9–94·1) 20·6 (17·3–31·5) 4·3 (3·0–4·9)
CD146+CCR6+ 27·6 (26·7–33·0) 1·3 (1·2–2·8) 21·2 (12·4–24·3)
CD161+ 45·5 (39·5–58·2) 12·1 (11·3–15·5) 3·3 (2·6–4·0)
CD146+CD161+ 14·1 (9·7–17·7) 1·0 (0·7–1·3) 9·1 (7·1–19·5)
RA (n = 8) CD146+ 30·9 (23·6–34·5) 3·0 (2·6–4·4) 8·7 (7·3–11·2)
CCR6+ 74·5 (65·4–82·4) 20·6 (15·8–35·6) 3·8 (2·3–5·2)
CD146+CCR6+ 24·4 (20·5–29·5) 1·3 (1·0–2·3) 18·3 (7·5–26·9)
CD161+ 55·2 (37·0–63·8) 11·7 (10·6–14·4) 4·3 (3·7–5·3)
CD146+CD161+ 17·9 (13·4–20·1) 1·0 (0·8–1·2) 17·7 (14·7–21·5)
Peripheral blood mononuclear cells (PBMCs) from patients or controls were analysed. CD4+IL-17+ (left column) or CD4+IL-17− T cells (middle
column) were gated and percentages of cells with the indicated phenotypes enumerated. Values for CD146+ cells represent the average of several meas-
urements, each in combination with a different surface marker. The ratio of percentages (IL-17+/IL-17−) is shown in the right-most column. Medians
are shown with interquartile ranges (IQR) in parentheses. The slight discrepancies between the median percentages of IL-17+ T helper (Th) cells
expressing CCR6 and CD161 reported in this Table and in Fig. 5 arose because of different sample sizes (not all patients were analysed for
co-expression), and because slightly different cut-offs for positivity were used. HD = healthy donors; PsA = psoriatic arthritis; AS = ankylosing
spondylitis; RA = rheumatoid arthritis.
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(Table 1, with representative examples in Fig. 7). In healthy
donors, CD146+CCR6+ cells were enriched approximately
21-fold among IL-17-producing (compared to non-
producing) Th cells (Table 1) – a much greater enrichment
than observed for CD146 alone (11-fold) or CCR6 alone
(3-fold). Similar trends were observed in arthritis patients
(Table 1). Thus, co-expression of CCR6 with CD146 was
more specific for IL-17-secreting Th cells than either
of these markers individually. Inevitably, however,
co-expression of CCR6 with CD146 was found on a slightly
smaller percentage of IL-17-secreting cells than expression
of CCR6 or CD146 individually (Table 1). Thus, the
CCR6+CD146+ phenotype was less sensitive at identifying
IL-17-secreting cells than the expression of either one of
these markers. Similarly, co-expression of CD161 with
CD146 was more specific and less sensitive for IL-17-
secreting cells than either marker individually in patients
and controls (Table 1). Given that CD26 and IL-23R indi-
vidually were not associated with IL-17 secretion, it is not
surprising that their co-expression with CD146 did not
improve sensitivity or specificity in relation to IL-17 pro-
duction (data not shown).
Relationship between CD146 expression and cytokine
secretion in synovial fluid
Compared with peripheral blood, the frequency of
CD146+CD4+ T cells was increased further in synovial fluid
from joints of patients with SpA or RA (Fig. 8a). In the SpA
group, results for PsA and AS were similar (data not
shown). This was consistent with selective recruitment of
CD146+CD4+ T cells to sites of inflammation. Cytokine-
secreting cells were attracted to the synovial fluid compart-
ment, albeit in a distinct pattern from that found in blood:
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Fig. 5. CD4+ CD146+ T cells are enriched for
dual cytokine-secreting cells. (a) Representative
analysis of CD4+ T cells from a
spondyloarthritis (SpA) patient, showing
isotype control staining or co-staining for
interleukin (IL)-17 with either IL-22 or
interferon (IFN)-γ. The analyses were gated
either on total CD4+ T cells (left) or on the
CD146+ and CD146− subsets within this
population (right), as indicated. (b) Frequencies
of IL-17+IL-22+ cells, compared in each group of
patients or healthy donors (HDs) between
CD146+ and CD146− CD4 T cells. Individual
data, geometric means and 95% confidence
intervals are shown on a log scale. Data were
log-transformed to equalize variances and
analysed using two-way analysis of variance
(anova), with matching of CD146+ and
CD146− data from each patient. The effect of
CD146 was significant in each patient group
(P < 0·001, Dunn’s post-test). There were no
significant differences between patient groups.
(c) Frequencies of IL-17+ IFN-γ+ cells, analysed
as in (b). The enrichment of dual cytokine
secretors in the CD146+ population was
significant (P < 0·001) in each patient group.
There were no significant differences between
patient groups.
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there was only slight enrichment of IL-17-secreting cells in
synovial fluid, no discernible enrichment for IL-22 and
marked enrichment for IFN-γ production (Fig. 8b–d).
If effector cytokine-secreting cells are recruited primarily
to synovial fluid by CD146-dependent pathways, one might
expect to find a greater enrichment of cytokine secretion
within the CD146+ subset in synovial fluid than in periph-
eral blood. The opposite was observed (Fig. 9). In synovial
fluid, IL-17-producing CD4 T cells were enriched within
the CD146+ subset, but only by 4-fold in SpA patients and
by approximately 4·6-fold in RA patients (geometric means;
versus 13-fold and 7·4-fold in blood, respectively, see
above). Comparing Fig. 4a with Fig. 9a, the main difference
between peripheral blood and synovial fluid was that a
greater proportion of CD146− CD4+ cells secreted IL-17 in
synovial fluid. IL-22 in synovial fluid also showed smaller
enrichments within CD146+CD4 T cells (1·7- and 2·6-fold,
respectively, in SpA and RA, Fig. 9b) than in peripheral
blood (4·8-fold for both); for IFN-γ, the trend was even
reversed (0·8- and 0·85-fold; Fig. 9c). Thus, even though
CD146 may play a role in the recruitment of effector Th
cells to synovial fluid, other factors must be at play to
account for the fact that enrichment of cytokine-secreting
effector cells in the CD146+ subset was less pronounced
than in peripheral blood.
Discussion
In this study, in patients with RA and two SpAs (AS and
PsA), as well as in healthy controls, we investigated the rela-
tionship between IL-17 production (following brief
polyclonal stimulation) and CD146 expression by CD4 T
cells ex vivo. Both in patients and in healthy donors, CD146+
cells were enriched for IL-17-producing cells and for surface
markers of Th17 cells. CD146+ cells were enriched even
further in synovial fluid of SpA patients. The frequency of
circulating CD146+CD4+ T cells was elevated above normal
in some patients with arthritis, correlating with ESR.
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Fig. 6. Association of CD146 expression with CCR6 and CD161. (a) Flow cytometry analysis of a representative spondyloarthritis (SpA) patient for
CD146 versus CCR6 or CD161, gated on CD4+ T cells. (b) Frequency of CCR6-expressing cells in the interleukin (IL)-17-secreting CD4 cells (grey
symbols), compared to CD146+ CD4 cells (black symbols) and CD146− CD4 cells (open symbols) in healthy donors (HDs) (circles) and patients
with SpA (triangles) and rheumatoid arthritis (RA) (squares). Individual data, medians and interquartile ranges are shown. Using two-way analysis
of variance (anova), both the differences between CD4 cell subsets (P < 0·0001) and those between subject groups (P = 0·0004) were significant.
Asterisks indicate significant pairwise differences between subsets (***P < 0·001; Dunn’s post-test). (c) Frequencies of CD161+ cells, analysed as in
(b). Using two-way anova, the differences between CD4 cell subsets (P < 0·0001) were significant, but there was no significant disease effect
(P > 0·05). Asterisks indicate significant pairwise differences between subsets (**P < 0·01; ***P < 0·001; Dunn’s post-test).
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Together, these data are consistent with a contribution of
CD146+ T cells to pathogenesis in inflammatory arthritis,
similar to conclusions from previous studies in other
autoimmune diseases (see Introduction). Our other find-
ings, however, indicate that the relationship between Th17
effector function, CD146 expression and inflammatory
recruitment is more complex than had been supposed pre-
viously. Importantly, CD146 by itself is neither a sensitive
nor a specific marker of Th17 cells, and combinations with
other markers, at best, improve specificity but reduce sensi-
tivity. CD146+CD4+ T cells in blood and synovial fluid are
heterogeneous in their patterns of IL-17, IFN-γ and IL-22
secretion; and CD146-dependent recruitment to sites of
inflammation does not account for cytokine secretion pat-
terns in synovial fluid.
Our results confirmed earlier findings [7–10] that Th17
cells are expanded in the blood of SpA patients. A similar
trend in RA had been reported previously, but did not reach
significance in our small RA cohort; this was also true for
the previously observed increase in IL-22-producing CD4
cells in SpA. Both the present study and previous work
showed that circulating Th1 cells are not expanded in SpA
or RA. Together, these findings are consistent with the
hypothesis that these inflammatory arthritides are driven in
part by excessive Th17 activity.
Furthermore, we confirmed recent findings [27] that
a subset of RA patients has increased frequencies of
circulating CD146+CD4 T cells, and report significantly
increased frequencies of CD146+ T cells in SpA. This
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Fig. 7. Relationship of effector cytokine secretion to coexpression of
CD146 with CCR6 or CD161. Analysis of a representative
spondyloarthritis (SpA) patient’s peripheral blood. Co-expression of
CD146 with CCR6 (a) or with CD161 (b) is shown, gated either on
IL-17-producing (left panels) or non-producing (right panels) CD4+ T
cells. Descriptive statistics for the different patient groups are
summarized in Table 1.
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Fig. 8. Frequencies of CD146+ and of
cytokine-producing Th cells in synovial fluid.
(a) CD146+ CD4 T-cell frequencies in
peripheral blood (as in Fig. 1c) versus synovial
fluid mononuclear cells from patients with
spondyloarthritis (SpA) [ankylosing spondylitis
(AS), n = 4; psoriatic arthritis (PsA), n = 10] and
rheumatoid arthritis (RA) (n = 4). Individual
data, medians and interquartile ranges are
shown. Statistical significance of the enrichment
in synovial fluid mononuclear cells (SFMC) was
assessed for each group by Mann–Whitney
U-test. (b–d) Comparison between peripheral
blood and synovial fluid of frequencies of
CD4+ T cells producing interleukin (IL)-17 (b),
IL-22 (c) and interferon (IFN)-γ (d). Analysis as
in (a).
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phenotype correlated with ESR, albeit weakly. The RA
group was older, on average, than healthy controls (see
Materials and methods), but the ages of the other groups
were not significantly different, and no systematic age
effect on CD146+CD4+ T cell frequencies was noted
(P > 0·05 for non-zero slope in each group by linear
regression). Moreover, there was no marked effect of
immunosuppressive therapies on CD146+CD4+ T cell fre-
quencies or PBMC yields in patients. However, our study
was not powered for a multivariate analysis, which would
be required to address the effects of clinical and demo-
graphic variables more definitively. Given that the fre-
quency of CD146+CD4+ T cells is elevated in various other
autoimmune conditions, which are treated with different
drug regimens, it seems likely that the increased frequen-
cies seen in AS on average, and in some RA patients,
reflect the autoimmune process, rather than the effect of
immunosuppression.
Both in the blood and synovial fluid of arthritis patients
and in the blood of HDs, circulating CD146+CD4+ T cells
were enriched for cytokine-producing Th effector cells. This
was expected from previous work showing relationships
of CD146 expression to recent or chronic T helper cell acti-
vation and effector function (cf. Introduction). Importantly,
the brief polyclonal stimulation protocol used here to elicit
effector cytokine production did not perturb CD146
expression. Of the cytokines examined, the fold enrichment
was greatest for IL-17, followed by IL-22, and least for
IFN-γ; in synovial fluid, however, the corresponding hierar-
chy was different: IFN-γ > IL-17 > IL-22.
As we have shown previously in healthy donors and con-
nective tissue disease patients [28], virtually all CD146+CD4
T cells are CD45RO+ memory cells, whereas CD146-
negative CD4 cells include both memory and naive popula-
tions in proportions that vary between individuals but
average approximately 50%. The admixture of naive CD4 T
cells would account for the ≈2-fold enrichment for IFN-γ in
the CD146+ population. In contrast, the much greater
enrichments observed in blood for IL-17 and IL-22 must be
due to coordinate expression of CD146 with these effector
cytokines. Collectively, these findings are consistent with
earlier reports that CD146+CD4 T cells are enriched for
Th17 effector function and related transcripts [22,24,26,27].
Unlike blood, synovial fluid Th cells are predominantly
memory cells, so admixture of naive cells causes little or no
bias in this compartment [34].
As expected from earlier studies of patients with arthri-
tis conditions (cf. Introduction), CD4+ T cells in arthritis
patients’ synovial fluid were enriched for CD146 expres-
sion compared to peripheral blood, supporting a role for
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Fig. 9. Cytokine production in CD146+ versus CD146− synovial fluid
T helper (Th) cells. (a)–(c) The percentages of cells expressing
interleukin (IL)-17 (a), IL-22 (b), or interferon (IFN)-γ (c) were
determined after gating on CD4+ cells with or without CD146, in
synovial fluid mononuclear cells (SFMC) samples from patients with
rheumatoid arthritis (RA) or spondyloarthritis (SpA). Individual
values are shown with geometric means and 95% confidence intervals.
For each patient group, data were log-transformed to equalize
variances; differences between matched CD146+ and negative cells
analysed by paired t-test (**P < 0·01; ***P < 0·0001).
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CD146 in T cell recruitment to arthritic joints and other
inflammatory sites. However, even in synovial fluid,
CD146+ cells comprised only a minority of infiltrating
CD4 cells. Moreover, IL-17- and IL-22-secreting cells were
enriched little, if at all, and the association with CD146
was less pronounced in synovial fluid. CD146 could be
down-regulated, shed or proteolysed following recruitment
of CD4+CD146+ cytokine-secreting T cells to inflammatory
sites; alternatively, CD146− effector Th cells might be
recruited by other extravasation mechanisms. Other com-
partments, such as synovial tissue, were not sampled in
this study. In any case, the elevated blood frequencies of
CD146+CD4+ T cells and IL-17-secreting Th cells in
patients must reflect a net balance of entry into blood (fol-
lowing clonal expansion of activated cells in lymph nodes
and/or at sites of inflammation) and recruitment to sites
of inflammation.
Interfering with trafficking of pathogenic effector T cells
to sites of inflammation is a potentially appealing therapeu-
tic strategy. For example, some of the effects of TNF block-
ade have been reported to reflect decreased recruitment of
cells to the joint, rather than simply neutralization of this
proinflammatory cytokine in the joint [35]. Our observa-
tional studies, however, cast doubt on the therapeutic
potential of CD146 blockade in SpA or RA, as this interven-
tion may prevent only a minority of effector T cells from
reaching inflamed joints. Although we did not perform
functional adhesion assays in this study this conclusion is
consistent with previous work in multiple sclerosis, where
Th17 cells showed a similar degree of enrichment among
CD146+CD4 cells, yet CD146 blockade diminished T cell/
endothelial interactions by only a small (albeit statistically
significant) amount [24].
Consistent with these findings, some putative Th17-
associated surface markers were also enriched substantially
in CD146+ CD4+ T cells. As reported previously [10,36],
≥80% of IL-17+CD4+T cells expressed CCR6, while ∼50%
expressed CD161 [37] – more than the 20–25% of
IL-17+CD4+ T cells which expressed CD146. Moreover, we
found CCR6 and CD161 to be enriched in CD146+ cells,
albeit less than in functional Th17 cells. CCR6 expression
on CD146+ CD4 cells may contribute to their selective
recruitment to synovial fluid, which is a source of the
CCR6 ligand, CCL20 [38]. Several other putative Th17-
related markers, however, were not enriched selectively in
either IL-17-producing or CD146-expressing CD4 cells.
Both subsets expressed CD26 at a high frequency, but so
did most CD4 T cells lacking CD146. Perhaps more sur-
prisingly, we found that only a minority of both subsets
expressed IL-23R, a receptor that enables IL-23 signalling
during Th17 differentiation and expansion. IL-23R may be
lost in cells which initially differentiated in response to
IL-23 and IL-6 (i.e. in the absence of TGFβ [39]), unless
expression is stabilized by further exposure to TGF-β and
IL-6 [1,2,40]. In any case, the close similarity in surface
phenotypes between CD146+ and IL-17-producing CD4 T
cells does not prove a functional relationship between these
two phenotypes.
Even though the enrichment for IL-17 producers in the
CD146+ subset was marked and robust in peripheral blood,
our data showed that CD146 expression on T cells is neither
a sensitive nor a specific marker of Th17 cells. Conceivably,
the frequency of both phenotypes might have been under-
estimated for technical reasons, but stimulation and detec-
tion conditions were carefully optimized and results in
healthy donors were consistent with earlier work. None the
less, IL-17 was produced by only a minority of CD146+ cells
under our stimulation conditions and, conversely, a major-
ity of IL-17 producers lacked detectable CD146 expression.
The combination of CD146 with either CCR6 or CD161
improved the specificity of association with IL-17 secretion,
consistent with previous work [30], but reduced sensitivity.
Two other putative Th17-related markers, CD26 and
IL-23R, showed no association with either IL-17 secretion
or CD146 expression, and co-expression of CD146 with
these markers did not improve delineation of IL-17-
secreting cells (not shown).
Moreover, T cells expressing other cytokines (IL-22 and
IFN-γ), mainly without IL-17, were also enriched in the
CD146+ subset. IFN-γ-secreting cells outnumbered IL-17-
secreting cells in this population, and IL-22-secreting cells
were only slightly less frequent. Thus, based on several lines
of evidence, CD146 marked subsets of effector T helper
cells with heterogeneous cytokine secretion patterns, with
IL-17-secreting cells comprising a minority, albeit a sub-
stantial one.
Further complexity arises from the fact that effector Th
cells may secrete combinations of cytokines and exhibit
functional plasticity. In mice, fate-mapping studies have
shown that repeated stimulation may result in activation of
IFN-γ production in cells that previously produced only
IL-17, followed by loss of IL-17 secretion and conversion to
‘ex-Th17’ cells [16,41]. In our study, a significant minority
of IL-17-producing CD4 cells (approximately 15%) also
secreted IFN-γ. These bifunctional Th1/17 cells were
enriched to a similar degree within the CD146+ population
as IL-17-secreting cells overall, whereas cells producing
IFN-γ without IL-17 were much less highly enriched. These
findings are consistent with the notion that the bifunctional
cells were derived from Th17 cells; the IFN-γ-secreting cells
may represent a mixture of ex-Th17 cells and conventional
Th1 cells in unknown proportions. Similar considerations
apply to cells secreting IL-22 with or without IL-17 [17].
These ideas will remain difficult to test directly, because
fate-mapping and gene knock-out approaches are unavail-
able in humans, and gene expression signatures or marker
profiles that distinguish conventionally differentiated Th17
cells [42] from bifunctional Th1/17 or Th17/22 cells,
ex-Th17 cells and conventional Th1 and Th22 cells are only
emerging in humans.
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Functional heterogeneity explains why there was no sig-
nificant correlation between CD146+ CD4 cell frequencies
and Th17 frequencies in either HDs or in RA patients’
blood (P > 0·05 each; Supporting information, Fig. S3a,b)
– the presence of other effector cell populations within the
CD146+ population and the lack of CD146 expression on
many Th17 cells would confound any such correlation.
Surprisingly, a statistically significant correlation was
observed in SpA (Supporting information, Fig. S3c) and,
within this group, appeared to be selective for PsA (data
not shown). PsA patients showed the greatest increase both
in Th17 and CD146+CD4 cell frequencies above healthy
controls, so in these circumstances a correlation may
emerge. Studies of larger patient populations would be
required to confirm this finding and to assess whether
this reflects disease-specific co-expression patterns, differ-
ences in the amount or quality of systemic inflammation
or confounding effects of therapy. In any case, taken
together these analyses confirmed that CD146 should not
be considered a surrogate marker of Th17 effector func-
tion, even though Th17 cells are enriched substantially
within this population. The correlation of CD146+CD4 T
cell frequencies with inflammatory markers is also weak.
Again, the likeliest explanation is the mixture of effector
phenotypes present in this population, not all of which
may be disease-relevant, and the possibility that effector
Th cell recruitment to inflammatory sites is partially
redundant.
To conclude, this study showed that the frequency of
CD146+CD4+ T cells is increased in peripheral blood from
patients with SpA and some patients with RA. In arthritis
patients and controls, IL-17 production and Th17-
associated surface markers are greatly enriched in
CD146+CD4 cells, but the functional repertoire of
CD146+CD4 cell populations includes secretion of IL-22
and IFN-γ, alone or with IL-17. CD146 may facilitate
migration of Th cells, secreting various effector cytokines,
from blood to the synovium through binding to endothelia,
but many effector Th cells in inflamed joints lack CD146
and alternative recruitment mechanisms may exist. CD146
is neither a sensitive nor a specific marker of Th17 cells and,
at best, a poor correlate of inflammation or disease activity
in inflammatory arthritis. The relationships between
CD146 expression and Th17 cytokine secretion may vary
between patient populations, but further studies would be
required to confirm this finding and assess its clinical
significance.
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Fig. S1. CD146 expression on CD4+ T cells is minimally
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expression.
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